Werbung
Werbung

GANX

GANX logo

Gain Therapeutics, Inc. Common Stock

2.30
USD
Gesponsert
-0.14
-5.78%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

2.35

+0.06
+2.44%

GANX Ergebnisberichte

Positives Überraschungsverhältnis

GANX übertreffen die 10 der letzten 19Schätzungen.

53%

Nächster Bericht

Datum des nächsten Berichts
25. März 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.14
Implizierte Änderung von Q3 25 (Revenue/ EPS)
--
/
-6.67%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
--
/
+27.27%

Gain Therapeutics, Inc. Common Stock earnings per share and revenue

On 12. Nov. 2025, GANX reported earnings of -0.15 USD per share (EPS) for Q3 25, beating the estimate of -0.15 USD, resulting in a 1.96% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +10.07% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of -0.14 USD, with revenue projected to reach -- USD, implying an decrease of -6.67% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
For Q3 2025, Gain Therapeutics, Inc. Common Stock reported EPS of -$0.15, beating estimates by 1.96%, and revenue of $0.00, 0% as expectations.
The stock price moved up 10.07%, changed from $2.68 before the earnings release to $2.95 the day after.
The next earning report is scheduled for 25. März 2026.
Based on 7 analysts, Gain Therapeutics, Inc. Common Stock is expected to report EPS of -$0.14 and revenue of -- for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung